In addition to finding that ELK4 overexpression was a biomarker of poor prognosis in CRC patients, we developed a nine‐gene prognostic signature derived from the ELK4‐SP1/3 complex‐regulated gene set (ESGS) to predict CRC patient outcomes. This evidence concerns the gene ELK4 and colorectal carcinoma.